Allogene Therapeutics Announces CFO Geoffrey Parker's Retirement
Allogene Therapeutics (ALLO) announced that Geoffrey Parker, its executive vice president and chief financial officer, will retire on November 6, 2026. The company noted that Parker will continue to lead the finance organization until his retirement date. Parker has played a key role in guiding Allogene's financial strategy during its growth phase as it develops cell-based therapies for cancer treatment. His departure is expected to be part of an orderly transition, with no immediate replacement named at this time. The announcement comes amid ongoing developments within the biotech sector and may influence investor sentiment around leadership stability.
Topics: CFO retirement executive change